Open an account

Neuphoria Therapeutics

NEUP · NASDAQ

$3.39+$0.08 (+2.42%)TodayMarket closed ·
Prev close $3.31

NEUP analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.
  • Strong buy0
  • Buy0
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $7.14 (+110.6% upside)

Low
$7.07
Now
$3.39
High
$7.35

Upgrades and downgrades

The latest rating actions, newest first

NEUP analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.May 15, 2026DowngradeBuy → Neutral
HC Wainwright & Co.Dec 5, 2025MaintainsBuy

The case for and against

Updated Feb 9, 2026

Bull case

Neuphoria Therapeutics Inc is advancing its drug candidate, BNC 210, showing promising results in clinical trials for treating neuropsychiatric disorders, particularly post-traumatic stress disorder (PTSD) and social anxiety disorder (SAD), with statistically significant improvements in symptom severity and safety profiles. Despite challenges associated with the Phase 3 SAD failure, the positive randomized Phase 2b PTSD data and an FDA agreement on a pivotal path forward lend credibility to the potential of BNC 210. The extensive patient exposure, with over 1,500 evaluations and a significant number treated long-term, further supports the drug's safety and underscores Neuphoria's commitment to addressing unmet medical needs within the central nervous system segment.

Bear case

Neuphoria Therapeutics demonstrates a negative outlook primarily due to the heightened risk profile associated with its drug candidate, BNC 210, which has encountered major setbacks, including a lack of efficacy in pivotal trials and ongoing issues with Lynx1, adding uncertainty to its development. Additionally, the company faces challenges related to securing adequate funding necessary for advancing its therapies, along with risks associated with potential dilutive capital raises and the possibility of failing to achieve commercial success. These factors collectively contribute to a deterioration in valuation and investor confidence, ultimately impacting the company's financial stability and growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.